Precision Antithrombotic Therapy

N/AEnrolling By InvitationNCT07654634

The Third Xiangya Hospital of Central South University5,000 enrolled

Overview

The goal of this observational study is to systematically analyze the relationship between trough/peak concentrations of novel oral anticoagulants (NOACs) and antiplatelet drugs with clinical events, aiming to provide high-level evidence for therapeutic drug monitoring (TDM) and personalized dosing.The main questions it aims to answer are: * What are the optimal preventive and therapeutic concentration ranges for different NOACs (rivaroxaban, apixaban, dabigatran, edoxaban) and antiplatelet drugs (aspirin, indobufen)? * What are the key factors influencing the blood drug concentrations of NOACs and antiplatelet drugs (such as liver and kidney function, age, weight, concomitant medications)? * How can we establish a model to predict blood drug concentrations of NOACs and antiplatelet drugs and their related clinical events? Participants will receive routine clinical care. During treatment, blood samples will be regularly collected to measure patients' blood drug concentrations (Ctrough and Cmax), and clinical responses and adverse events will be recorded.

Study Type

OBSERVATIONAL

Enrollment

5,000

Conditions

Non-valvular Atrial Fibrillation (NVAF)Venous Thromboembolism (VTE)MI(Myocardial Infarction)Ischemic Stroke

Eligibility

Sex: ALLMin age: 8 Years

Medical Language ↔ Plain English

Inclusion criteria: * Age ≥ 8 years old; * Diagnosed with one of the following diseases and in need of long - term anticoagulant therapy: non - valvular atrial fibrillation (CHA₂DS₂ - VA score ≥ 1); venous thromboembolism (deep vein thrombosis or pulmonary embolism); having other indications for using NOACs to prevent and treat thrombotic diseases; * Currently receiving NOAC treatment (rivaroxaban, apixaban, dabigatran etexilate, edoxaban); * Willing and able to comply with the requirements of the research protocol and the follow - up plan; * Signed the informed consent form. * Age ≥ 18 years old; * Assessed as patients at high risk of bleeding within 72 hours after the onset of symptoms; * Receiving indobufen treatment for the first time after admission; * Willing and able to comply with the requirements of the research protocol and the follow - up plan; * Signed the informed consent form. Exclusion criteria: * Having contraindications to the use of NOACs or being allergic to NOACs; * Having been enrolled in other clinical trials. * Being allergic to or having contraindications to indobufen; * Needing to change antithrombotic drugs or combine with other antiplatelet/anticoagulant therapies (such as clopidogrel, ticagrelor, warfarin, heparin, etc.) during the study; * Cardiogenic stroke or stroke induced by angioplasty/vascular surgery; * Having a history of aneurysm (intracranial or peripheral); * Severe abnormal liver and kidney functions; * Pregnant, lactating women or women of childbearing age who are unwilling to take effective contraceptive measures; * Life expectancy \< 1 year; * Mental or emotional disorders preventing cooperation with follow - up; * Participating in other clinical trials within 30 days before enrollment; * Unable to complete blood concentration detection (such as difficulty in establishing venous access).

Outcomes

Primary Outcomes

Efficacy Endpoint: Composite thrombotic events (ischemic stroke, systemic embolism, myocardial infarction, deep vein thrombosis, pulmonary embolism)

Time frame: At the 1st month, 3rd month and 6th month after enrollment

Safety Endpoint: Bleeding events (major bleeding and clinically relevant non-major bleeding)